These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 1197256)

  • 21. [Studies on the significance of middle molecular retention products as uremia toxins].
    Goubeaud G; Leber HW; Schott HH
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():1244-6. PubMed ID: 611827
    [No Abstract]   [Full Text] [Related]  

  • 22. [Survey on uremic polyneuritis].
    Rojas P; Degoulet P; Jacobs C; Legrain M
    J Urol Nephrol (Paris); 1977 Dec; 83(12):985-97. PubMed ID: 609112
    [No Abstract]   [Full Text] [Related]  

  • 23. Uremic toxins.
    Ringoir S; Schoots A; Vanholder R
    Kidney Int Suppl; 1988 Mar; 24():S4-9. PubMed ID: 3283412
    [No Abstract]   [Full Text] [Related]  

  • 24. The road toward the identification of middle molecules. Preliminary Committee Meeting, Avignon, France November 28-29, 1980.
    Bergstrom J; Funck-Brentano JL; Klinkmann H
    Artif Organs; 1980 Aug; 4(3):209-10. PubMed ID: 7417037
    [No Abstract]   [Full Text] [Related]  

  • 25. [Medium-sized molecules and the process of uremic intoxication].
    Lutz W
    Pol Tyg Lek; 1976 Jul; 31(27):1173-6. PubMed ID: 951302
    [No Abstract]   [Full Text] [Related]  

  • 26. ["The middle molecules" are uremic toxins (author's transl)].
    Hanicki Z; Cichocki T
    Przegl Lek; 1978; 35(2):301-5. PubMed ID: 652997
    [No Abstract]   [Full Text] [Related]  

  • 27. Inhibition of phagocytosis by a middle molecular fraction from ultrafiltrate.
    Ringoir SM; van Landschoot N; de Smet R
    Clin Nephrol; 1980 Mar; 13(3):109-12. PubMed ID: 7379359
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Uremic middle molecules: separation and quantitation.
    Chapman GV; Farrell PC
    Artif Organs; 1981; 4 Suppl():160-5. PubMed ID: 7295084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dialysis therapy: 'think differently'.
    Perrone B
    Nephrol Dial Transplant; 2007 Jul; 22 Suppl 5():v1-2. PubMed ID: 17586840
    [No Abstract]   [Full Text] [Related]  

  • 30. Separation and characterization of uremic metabolites in biologic fluids: a screening approach to the definition of uremic toxins.
    Gordon A; Berström J; Fürst P; Zimmerman L
    Kidney Int Suppl; 1975 Jan; (2):45-51. PubMed ID: 1057692
    [No Abstract]   [Full Text] [Related]  

  • 31. What remains of the "middle molecule" hypothesis today?
    Brunner H; Mann H
    Contrib Nephrol; 1985; 44():14-39. PubMed ID: 3886282
    [No Abstract]   [Full Text] [Related]  

  • 32. Uraemic peripheral neuritis persisting after renal transplantation.
    Taaffe A
    Br J Clin Pract; 1978 Feb; 32(2):57-8. PubMed ID: 352381
    [No Abstract]   [Full Text] [Related]  

  • 33. Characterization of a 1100-1300 MW uremic neurotoxin.
    Funck-Brentano JL; Man NK; Sausse A; Zingraff J; Boudet J; Becker A; Cueille GF
    Trans Am Soc Artif Intern Organs; 1976; 22():163-7. PubMed ID: 951836
    [No Abstract]   [Full Text] [Related]  

  • 34. Technical aspects on middle molecules: separation, isolation, and identification.
    Cueille G; Man NK; Sausse A; Farges JP; Funck-Brentano JL
    Artif Organs; 1981; 4 Suppl():8-12. PubMed ID: 7295100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paired filtration-dialysis (PFD): a separate convective-diffusive system for extracorporeal blood purification in uraemic patients.
    Ghezzi PM; Zucchelli P; Ringoir S; Nigrelli S; Santoro A; Gervasio R; Sanz Moreno C; Vanholder R; Botella J
    Adv Exp Med Biol; 1987; 223():267-75. PubMed ID: 3328955
    [No Abstract]   [Full Text] [Related]  

  • 36. Concentration of plasma middle molecular weight substances and clinical condition of patients undergoing short-time regular dialysis treatment.
    Válek A; Dzúrik R; Spustová V; Válková D
    Artif Organs; 1981; 4 Suppl():173-6. PubMed ID: 7295088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemical analytic approaches to the definition of uremic toxins.
    Furst P; Bergstrom J; Gordon A; Zimmermann L
    Ateneo Parmense Acta Biomed; 1975; 46(5):307-16. PubMed ID: 1232992
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genesis of the uraemic syndrome: role of uraemic toxins.
    Hörl WH
    Wien Klin Wochenschr; 1998 Aug; 110(15):511-20. PubMed ID: 9782569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Middle molecular weight substances and uremic polyneuropathy.
    Dukanović L; Petrović J; Potić J
    Acta Med Iugosl; 1990; 44(2):117-28. PubMed ID: 2162129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Middle molecules and the problem of endogenous intoxication in critical states of various etiologies].
    Vladyka AS; Levitskiĭ ER; Poddubnaia LP; Gabriélian NI
    Anesteziol Reanimatol; 1987; (2):37-42. PubMed ID: 3300433
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.